



(12) **United States Patent**
Andrews et al.

(10) **Patent No.: US 6,713,481 B1**
(45) **Date of Patent: Mar. 30, 2004**

(54) **CRYSTALLINE ANTIFUNGAL POLYMORPH**

(76) **Inventors:** David R. Andrews, 449 Baldwin Rd.,
Maplewood, NJ (US) 07040; William
Leong, 705 Carleton Rd., Westfield, NJ
(US) 07090; Anantha Sudhakar, 18
Snowden Rd., East Brunswick, NJ (US)
08816

(*) **Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 721 days.

(21) **Appl. No.: 09/166,445**

(22) **Filed: Oct. 5, 1998**

Related U.S. Application Data

(60) **Provisional application No. 60/061,231, filed on Oct. 17,
1997.**

(51) **Int. Cl.⁷ A61K 31/496; C07D 405/14**

(52) **U.S. Cl. 514/254.07; 544/366**

(58) **Field of Search 544/366; 514/252,
514/254.07**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,625,064 A	• 4/1997	Andrews et al.	544/366
5,661,151 A	• 8/1997	Saksena et al.	514/252
5,693,626 A	• 12/1997	Saksena et al.	514/85
5,703,079 A	• 12/1997	Saksena et al.	514/252
5,710,154 A	• 1/1998	Saksena et al.	514/252
5,714,490 A	• 2/1998	Saksena et al.	514/252

FOREIGN PATENT DOCUMENTS

WO	95/17407	• 6/1995
WO	96/33178	10/1996
WO	96/38443	• 12/1996

OTHER PUBLICATIONS

Munzel, Von K., *Progress in Drug Research*, 1996, vol. 10,
pp. 227-230, Birkhauser, Basel, Switzerland.


* cited by examiner

Primary Examiner—Emily Bernhardt

(74) *Attorney, Agent, or Firm*—Thomas D. Hoffman

(57) **ABSTRACT**

The crystalline polymorph Form I of (-)-4-[4-[4-[(2R-
cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-
1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]
phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-
3H-1,2,4-triazol-3-one represented by the formula I



pharmaceutical compositions containing such a polymorph
and methods of using such a polymorph to treat fungal
infections in mammals are disclosed.

5 Claims, 10 Drawing Sheets